NZ517538A - Drug for treating fractures - Google Patents

Drug for treating fractures

Info

Publication number
NZ517538A
NZ517538A NZ517538A NZ51753800A NZ517538A NZ 517538 A NZ517538 A NZ 517538A NZ 517538 A NZ517538 A NZ 517538A NZ 51753800 A NZ51753800 A NZ 51753800A NZ 517538 A NZ517538 A NZ 517538A
Authority
NZ
New Zealand
Prior art keywords
bone
drug
medicament
manufacture
group
Prior art date
Application number
NZ517538A
Other languages
English (en)
Inventor
David Graham Little
Original Assignee
Royal Alexandra Hosp Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Alexandra Hosp Children filed Critical Royal Alexandra Hosp Children
Publication of NZ517538A publication Critical patent/NZ517538A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ517538A 1999-08-19 2000-08-17 Drug for treating fractures NZ517538A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures
PCT/AU2000/000982 WO2001013922A1 (fr) 1999-08-19 2000-08-17 Medicament pour traiter des fractures

Publications (1)

Publication Number Publication Date
NZ517538A true NZ517538A (en) 2003-07-25

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ517538A NZ517538A (en) 1999-08-19 2000-08-17 Drug for treating fractures

Country Status (16)

Country Link
EP (1) EP1214079A4 (fr)
JP (1) JP2003507426A (fr)
KR (1) KR20020027562A (fr)
CN (1) CN100345548C (fr)
AU (1) AUPQ232599A0 (fr)
BR (1) BR0013416A (fr)
CA (1) CA2381302A1 (fr)
HK (1) HK1048441B (fr)
HU (1) HUP0202396A3 (fr)
IL (1) IL148166A0 (fr)
NO (1) NO20020784L (fr)
NZ (1) NZ517538A (fr)
PL (1) PL353485A1 (fr)
SK (1) SK2382002A3 (fr)
WO (1) WO2001013922A1 (fr)
ZA (1) ZA200202160B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365769B1 (fr) * 2001-02-06 2011-01-26 The Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children) Medicament destine au traitement de l'osteonecrose et a la gestion de patients etant predisposes a l'osteonecrose
AU2002244520B2 (en) * 2001-04-03 2007-05-24 The Royal Alexandra Hospital For Children A drug for use in bone grafting
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
CA2539359A1 (fr) * 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un bisphosphonate
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
ES2379485T3 (es) * 2005-10-27 2012-04-26 Thommen Medical Ag Implante dental y procedimiento para su fabricación
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8107560A (pt) * 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
EP0600834A1 (fr) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Utilisation de dérivés de l'acide méthanediphosphonique pour la fabrication d'un médicament pour le traitement de fractures
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
WO1994014455A1 (fr) * 1992-12-23 1994-07-07 Merck & Co., Inc. Therapie utilisant des bisphosphonates et des ×strogenes en vue de traiter et de prevenir la resorption osseuse
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
WO1996039150A1 (fr) * 1995-06-06 1996-12-12 Merck & Co., Inc. Traitement par bisphosphonates de la deperdition osseuse associee a l'arthrite rhumatoide
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds

Also Published As

Publication number Publication date
KR20020027562A (ko) 2002-04-13
ZA200202160B (en) 2003-08-27
IL148166A0 (en) 2002-09-12
CA2381302A1 (fr) 2001-03-01
JP2003507426A (ja) 2003-02-25
NO20020784D0 (no) 2002-02-18
WO2001013922A1 (fr) 2001-03-01
PL353485A1 (en) 2003-11-17
BR0013416A (pt) 2002-04-30
HUP0202396A3 (en) 2005-02-28
CN1370071A (zh) 2002-09-18
CN100345548C (zh) 2007-10-31
HK1048441A1 (en) 2003-04-04
SK2382002A3 (en) 2002-09-10
HUP0202396A2 (hu) 2002-11-28
HK1048441B (zh) 2008-02-22
AUPQ232599A0 (en) 1999-09-09
EP1214079A4 (fr) 2004-03-24
NO20020784L (no) 2002-02-18
EP1214079A1 (fr) 2002-06-19

Similar Documents

Publication Publication Date Title
Yıldız et al. Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model
WO2002098307A1 (fr) Dispositif permettant l'apport d'un medicament a un os fracture
Little et al. Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis: A study in immature rabbits
US20040157798A1 (en) Drug for use in bone grafting
Pampu et al. Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis
Cuairán et al. Local application of zoledronate enhances miniscrew implant stability in dogs
Küçük et al. Comparison of local and systemic alendronate on distraction osteogenesis
Little et al. Effect of pamidronate on distraction osteogenesis and fixator-related osteoporosis
CN105012995B (zh) 一种含促骨愈合药物的胶原蛋白海绵及其制备方法
NZ517538A (en) Drug for treating fractures
Oteo-Álvaro et al. Teriparatide (rh [1–34] PTH) improved osteointegration of a hemiarthroplasty with signs of aseptic loosening
EP2953632A1 (fr) Carbonate de calcium amorphe pour croissance osseuse accélérée
Linderbäck et al. Weak effect of strontium on early implant fixation in rat tibia
Tarvainen et al. Effect of clodronate on fracture healing in denervated rats
Harding et al. A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients
AU781068B2 (en) Drug for treating fractures
CA2353528C (fr) Utilisation d'ibandronate pour favoriser l'osseointegration des endoprotheses
Alshahrani et al. Ranitidine impairs bone healing and implant osseointegration in rats' tibiae
Kakar et al. Can we improve fixation and outcomes in the treatment of femoral neck fractures? The use of pharmaceuticals
Saghieh et al. The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: an animal model study
KR102451667B1 (ko) 골, 연골, 치아 및 치주의 재생 및 종양 및 낭포의 치료를 위한 제형
Heidari et al. Effect of risedronate on bone resorption during the consolidation phase of distraction osteogenesis: a rabbit model
Shibahara et al. Histological evaluation of the low-density region around beta-tricalcium phosphate scaffolds used in opening wedge high tibial osteotomy: A report of two cases
Min et al. Nonsurgical treatment strategies after osteoporotic hip fractures
Savintsev et al. Application of nanostructured carbon implants in surgical treatment of transverse flat feet

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)